newsfilter
← Latest News
Business Wire·

Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026 Announced Progress with Wholly-Owned Corneal Endothelial Disease Cell Therapy Program